CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Metastatic Castration-Resistant Prostate Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
<< View More Conferences
2017 AACR Annual Meeting
Oncology Conference Multimedia
View more videos >>
Dr. Agarwala on the Significance of OS and Toxicity Results in CheckMate-067
Dr. Dreyling on Results for Copanlisib in Patients With B-Cell Lymphoma
Dr. Wolchok on Weighing Risk and Benefit of Nivolumab/Ipilimumab Combo in Melanoma
Oncology Conference Articles
Kite Unveils Novel BCMA-Directed CAR T-cell Therapy
A novel target, B-cell maturation antigen, has been identified for future therapeutic development as chimeric antigen receptor T-cell therapy for patients with multiple myeloma.
PI3K Inhibitor Copanlisib Active in Relapsed/Refractory Lymphoma
According to results from the phase II CHRONOS-1 trial, a majority of patients with relapsed or refractory indolent lymphoma responded to treatment with the PI3K dual-isoform inhibitor copanlisib.
CAR T Cell Functionality Correlates With Outcomes, Offering a Biomarker for Response
The flexibility of CAR T cells to perform multiple functions was associated with the level of clinical activity elicited for patients with advanced non-Hodgkin’s lymphoma, according to a retrospective analysis presented at the 2017 AACR Annual Meeting.
IDO Inhibitor Increases Pembrolizumab Response in Melanoma
Adding the IDO inhibitor indoximod to pembrolizumab led to an overall response rate of 52% in patients with advanced melanoma, according to findings from a phase II trial reported at the 2017 AACR Annual Meeting.
Novel IDO1 Inhibitor Shows Promise in Early Phase Study
The IDO1 inhibitor BMS-986205 had "best-in-class" activity as demonstrated by kynurenine reductions and IDO1 inhibition for patients with advanced malignancies in a phase I/IIa study, according to lead investigator Lillian L. Siu, MD, at the 2017 AACR Annual Meeting.
Adding Coxsackievirus to Ipilimumab Displays Durable Antitumor Activity in Advanced Melanoma
Adding a formulation of the Coxsackievirus A21 (CAVATAK
) to ipilimumab (Yervoy) yielded an overall response rate of 50% and was well-tolerated in immunotherapy-naïve and pretreated patients with advanced melanoma.
Function of IDH Mutations Can Be Exploited by PARP Inhibitors Instead of IDH Inhibitors
A phase II basket trial has been announced to test that mutations in isocitrate dehydrogenase 1 and 2 are not driver mutations that should be targeted with direct IDH inhibitors, but instead they create vulnerabilities that can be exploited through treatment with PARP inhibitors.
Novel RAF Inhibitor Active Across Multiple Tumor Types
Treatment with the RAF dimer inhibitor BGB-283 led to clinical benefit for patients with
V600-mutated melanoma, papillary thyroid cancer, and ovarian cancer.
CAR T-Cell Response Rate Tops 80% in NHL Trial
Results of a phase II trial showed that more than 80% of patients with refractory non-Hodgkin lymphoma achieved objective responses to treatment with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel.
Five-Year Survival Rate an Impressive 16% With Nivolumab in Advanced NSCLC
Long-term survival in patients with metastatic non–small cell lung cancer who received the immune checkpoint inhibitor nivolumab (Opdivo) has proven to be much higher than expected, with 16% of these patients surviving after 5 years, equivalent to about 4 times what would be expected with chemotherapy.
Nivolumab/Ipilimumab Combo Shows Modest OS Benefit in Advanced Melanoma in Updated Phase III Findings
The PD-1 and CTLA-4 inhibitor combination of nivolumab (Opdivo) and ipilimumab (Yervoy) was associated with a 12% reduction in the risk of death versus nivolumab monotherapy in patients with treatment-naïve advanced melanoma.
Avelumab Further Demonstrates Durable Responses in Merkel Cell Carcinoma
Treatment with the PD-L1 inhibitor avelumab induced an objective response rate of 33% in patients with advanced Merkel cell carcinoma in the phase II JAVELIN Merkel 200 study, including 2 additional complete responses since the primary analysis.
Atezolizumab Yields Long-Term OS in mTNBC Subset
According to results presented at the 2017 AACR Annual Meeting, 10% of patients showed impressive long-term survival in a phase I study of single agent anti-PD-L1 atezolizumab (Tecentriq) in patients with metastatic triple-negative breast cancer.
Tumor Treating Fields Substantially Improve Survival in GBM
Tumor treating fields reduced the risk of death by 37% and overall survival was extended by a median of 5 months for patients with glioblastoma multiforme, in a landmark analysis of the EF-14 trial.
Dual HER2 Targeting Effective in Refractory mCRC Subset
A dual attack on HER2 expression resulted in a 30% objective response rate in heavily pretreated patients with HER2-positive metastatic colorectal cancer.
Neratinib Shows Promise in HER2-Mutated Cancers
The irreversible pan-HER tyrosine kinase inhibitor neratinib showed single-agent activity across cohorts of patients with
-mutant advanced cancers.
Burden of Cardiovascular Disease in Prostate Cancer
The Role of Patient Education in Side Effect Management
Sorting Through the Alphabet Soup of Evolving Treatments in CLL
Larotrectinib Inches Closer to FDA Approval for TRK+ Cancers
FDA Warns Against Single-Agent Checkpoint Inhibition for PD-L1-Low Untreated Urothelial Carcinoma
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.